NSRX AMEX
Nasus Pharma Ltd.
1W: +12.6%
1M: +4.0%
3M: +13.9%
YTD: -48.1%
1Y: -34.7%
$3.92
+0.10 (+2.75%)
Weekly Expected Move ±8.5%
$3
$4
$4
$4
$5
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider+$0.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$33.8M
52W Range1.98-9.5
Volume28,687
Avg Volume23,632
Beta4.20
Dividend—
Analyst Ratings
Company Info
CEOBrendan O'Grady
Employees7
SectorHealthcare
IndustryMedical - Pharmaceuticals
IPO Date2025-08-13
Websitenasuspharma.com
Yigal Alon 65
Tel Aviv, TA 6744317
IL
Tel Aviv, TA 6744317
IL
97235736632
About Nasus Pharma Ltd.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Latest News
Nasus Pharma Announces Enrollment and Dosing of First Patient in Phase 1 Study of NS003 Intranasal Formulation of Ondansetron
Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis
Nasus Pharma Reports First Half 2026 Financial Results and Provides Business Update
Nasus Pharma (NYSEAMERICAN:NSRX) Trading Up 9.7% – Here’s Why
NSRX: NS002 June KOL Event
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rubin Eyal | 0 | — | 2026-09-18 | |
| O'Grady Brendan P. | 0 | — | 2026-07-27 | |
| Teleman Dan Benjamin | 0 | — | 2026-07-22 | |
| Teleman Dan Benjamin | P-Purchase | 6,550 | $3.10 | 2026-06-17 |
| Teleman Dan Benjamin | P-Purchase | 2,900 | $3.76 | 2026-04-22 |